Confirmed pathology
Biopsy or surgical pathology should clearly confirm NSCLC and, when possible, the histologic subtype and immunohistochemistry profile.
Oncology evaluation directory
Thoracic oncology
Non-small Cell Lung Cancer Evaluation
A physician-led file review for documented NSCLC, organized around histology, stage, molecular profile, prior therapy, current symptoms and the practical question of whether a Cuba-related oncology discussion is appropriate.
Medical disclaimer: This page is informational and coordination-focused. It does not diagnose, prescribe, promise treatment suitability or replace urgent local medical care.
Clinical file logic
What the specialist needs to understand before any treatment discussion.
Non-small cell lung cancer is not reviewed as a single generic diagnosis. The medical file must show whether the tumor is adenocarcinoma, squamous cell carcinoma or another NSCLC subtype, because this can affect biomarker testing, treatment history, safety questions and specialist interpretation.
For international coordination, the most important work is not to promise a treatment. It is to organize the file so the reviewing physician can understand what has been confirmed, what is still uncertain, what has already been tried and what the patient is asking to evaluate.
Current stage and disease distribution
Recent CT, PET-CT, brain imaging when clinically relevant and reports describing lymph nodes, pleura, liver, bone, adrenal or brain involvement are organized.
Molecular and immune profile
EGFR, ALK, ROS1, BRAF, MET exon 14, RET, NTRK, KRAS, HER2 and PD-L1 are reviewed when available; missing tests are clearly marked rather than assumed.
Prior treatment response
Surgery, radiotherapy, platinum chemotherapy, immunotherapy, targeted therapy, maintenance therapy and dates of progression are summarized in sequence.
Performance and risk status
Shortness of breath, oxygen use, pleural effusion, pain, weight loss, infection, organ function and treatment tolerance are reviewed before travel or treatment planning discussions.
The specialist question
The file should ask a precise question: second opinion, suitability discussion, supportive care route, post-progression options or Cuba-based evaluation.
Evaluation matrix
How the case is reviewed without reducing it to a diagnosis name.
Each item below affects how the file is interpreted, what the physician can answer and whether additional documents are needed before a responsible response.
Pathology integrity
Report date, tissue source, immunohistochemistry and whether the diagnosis is primary lung cancer or metastasis from another tumor are checked.
Biomarker completeness
Molecular and PD-L1 results help frame the discussion and avoid ignoring standard targeted or immunotherapy considerations.
Disease tempo
Slow progression, rapid symptomatic decline, oligometastatic disease and widespread progression are not reviewed the same way.
Cuba discussion boundary
CIMAvax-EGF or Vaxira are presented only as physician-review topics for selected contexts, never as universal or guaranteed cancer treatment.
Documents to prepare
A complete medical file prevents delay and unrealistic expectations.
Most delays happen when the diagnosis is described verbally but the file lacks dates, reports, imaging, pathology or the current specialist recommendation. The documents below are requested before the file is considered ready for review.
Cuba context
How Cuba-related options are framed responsibly.
The page does not present a hospital visit or travel plan as automatically suitable. Any Cuba-related discussion remains conditional on physician review of the current file.
Standard oncology remains the baseline
Surgery, systemic therapy, radiation, targeted therapy, immunotherapy and supportive care remain physician-led according to stage, biomarker status and prior response.
Cuban biotechnology is reviewed carefully
CIMAvax-EGF and Vaxira may be discussed only after the file is reviewed and only when the clinical context is relevant.
Travel is not the first decision
The first decision is whether the file is complete enough for a responsible specialist opinion. Travel or treatment logistics come later.
Options discussed in Cuba
Cuba-related options in lung cancer and what the evidence shows
CIMAvax-EGF is licensed in Cuba for advanced non-small cell lung cancer (stages IIIb/IV), and Vaxira carries a maintenance indication after first-line treatment. The information below is taken from the approved product summaries.
In non-small cell lung cancer the Cuba-related products most often raised are the therapeutic vaccines CIMAvax-EGF and Vaxira (racotumomab). CIMAvax-EGF aims to make the body produce antibodies against its own epidermal growth factor, reducing the stimulation of tumour cells that depend on that signal. Vaxira targets NeuGcGM3, a structure that can appear on tumour cell surfaces. Both are given by intramuscular injection, with induction doses followed by monthly maintenance.
CIMAvax-EGF has been licensed in Cuba for advanced NSCLC since 2008 and has been used in more than 1,000 patients across 13 clinical trials. In the published phase III trial the per-protocol analysis showed a favourable survival signal, while the intention-to-treat comparison did not reach statistical significance. Research continues, including combination trials with checkpoint inhibitors in the United States. Where a driver alteration (EGFR, ALK, ROS1) or high PD-L1 is present, proven targeted therapy and checkpoint inhibitors take priority.
Nimotuzumab (CIMAher), an EGFR-directed antibody used in head and neck disease, may also be mentioned in a lung cancer context. Indication, combination and sequencing remain decisions for the oncologist who reviews the complete file. Nothing on this page is a recommendation to change current treatment.
Who it is studied in
Published use is mainly as maintenance in patients who have completed first-line therapy, whose disease is controlled to some degree and whose performance status is good.
Continuity of dosing
Monthly maintenance means the place of administration, product supply and local oncology follow-up must be agreed in writing before any travel is booked.
Licensing status
These products are licensed in Cuba and some other countries; they are not approved for routine use in the EU or the United States. Administration is planned where they are licensed and in an authorised centre.
When local care comes first
Do not wait for international review if urgent symptoms are present.
International coordination should never delay emergency care. If any of the following are present, the patient should be assessed locally first.
- Severe shortness of breath, oxygen instability or chest pain.
- Coughing blood, suspected pulmonary embolism, fever with low white blood cells or uncontrolled infection.
- New neurological symptoms, uncontrolled pain, spinal cord compression concern or rapidly worsening performance.
Coordination pathway
From records to written next steps.
- File intakeReports, imaging, summaries and current symptoms are uploaded through the application flow.
- Quality checkThe coordination team checks readability, dates, translation needs and missing items.
- Specialist routingThe case is prepared around a clear medical question and routed to the relevant review pathway.
- Written responseThe patient receives an organized next-step explanation before travel, payment or treatment logistics are considered.
Questions
Before starting the application.
Does this page mean I am suitable for a Cuba-based treatment?
No. It explains how the file is organized for review. Suitability, route, timing and safety can only be determined by physicians after reviewing the complete current record.
Can I send only a short summary?
A summary helps, but it is not enough for most oncology reviews. Pathology, imaging, treatment history, lab results and the latest oncology note are usually needed.
Will the coordinator choose my treatment?
No. Cuba Health Assist coordinates records, communication, translation support and logistics. Medical decisions remain with licensed physicians and the patient’s treating team.
What happens if my file is incomplete?
The team will request missing reports before presenting the case as ready. This protects the patient from receiving a weak or unrealistic response.
Can urgent symptoms be handled through this page?
No. Severe or rapidly worsening symptoms require local emergency or oncology care first. International coordination is not an emergency service.
Related evaluation pages
Other oncology files reviewed in the same clinical directory.
Official product information
CIMAvax-EGF as licensed in Cuba
The data below are taken from the product summary approved by CECMED, the Cuban medicines regulator. They describe the product as licensed in Cuba and are not a treatment recommendation.
- Registration
- Sanitary registration B-08-063-L03, registered 12 June 2008
- Manufacturer
- Center of Molecular Immunology (CIM), Havana, Cuba
- Approved indication
- Non-small cell lung cancer in advanced stages IIIb / IV
- Route and schedule
- Intramuscular. Each dose is four injections (both gluteal and both deltoid regions), 1.2 mL each. Induction begins with a single dose of cyclophosphamide 200 mg/m²; three days later the vaccine is given every 14 days for the first four doses. Maintenance is monthly re-immunisation for as long as the patient's general condition allows.
- Contraindications
- Pregnancy and breastfeeding; history of allergy to chemically or biologically similar compounds; uncontrolled intercurrent disease including active infection, symptomatic congestive heart failure, unstable angina and cardiac arrhythmia; hypersensitivity to cyclophosphamide; paediatric use. Caution in renal or hepatic impairment.
- Safety profile
- More than 1,000 patients with advanced lung cancer in 13 clinical trials. Most adverse events were mild or moderate: flushing, loss of appetite, cramps, chills, tremor, headache, nausea, vomiting, fever, breathlessness, hot flushes, raised or lowered blood pressure, and redness or pain at the injection site.
- Prescribing
- Treatment may only be started under the supervision of a physician experienced in oncology care.
Approval in Cuba does not mean approval in your country, and it does not mean the product is suitable for you. Eligibility is decided by the physician who reviews your complete file.
Official product information
Vaxira (racotumomab) as licensed in Cuba
The data below are taken from the product summary approved by CECMED, the Cuban medicines regulator. They describe the product as licensed in Cuba and are not a treatment recommendation.
- Registration
- Sanitary registration B-13-001-L03C, registered 7 January 2013
- Manufacturer
- Center of Molecular Immunology (CIM), Cuba
- Approved indication
- Non-small cell lung cancer in advanced stages IIIb or IV, in patients with an objective clinical response or stable disease after first-line chemotherapy and radiotherapy — that is, switch maintenance.
- Route and schedule
- Intradermal. Each 1 mg dose is divided into four sub-doses of 0.25 mL given at four different sites: deltoid region, front of the forearm, front of the thigh and back of the calf. Induction: the first five doses 14 days apart. Maintenance: re-immunisation every 28 days until unacceptable toxicity or deterioration in general condition.
- Monitoring
- For the first two doses the patient is observed for one hour so that any immediate reaction can be detected and treated. No premedication is required.
- Contraindications
- History of hypersensitivity to chemically or biologically similar compounds, or to any component of the formulation.
- Safety profile
- More than 500 patients with advanced lung cancer across clinical trials; generally well tolerated. Most common were local reactions (redness and pain at the injection site) and systemic effects such as headache, chills, tremor, sweating, feeling cold, breathlessness and malaise.
Approval in Cuba does not mean approval in your country, and it does not mean the product is suitable for you. Eligibility is decided by the physician who reviews your complete file.
Start with the file
Submit documents before making a travel or treatment decision.
A coordinator will organize the medical information and guide the next step according to specialist review. The process is designed to be transparent, clinically cautious and written.